stoxline Quote Chart Rank Option Currency Glossary
  
ABVC BioPharma, Inc. (ABVC)
0.855  -0.115 (-11.86%)    04-17 16:00
Open: 0.95
High: 0.95
Volume: 225,173
  
Pre. Close: 0.97
Low: 0.85
Market Cap: 13(M)
Technical analysis
2025-04-17 4:46:57 PM
Short term     
Mid term     
Targets 6-month :  1.28 1-year :  1.63
Resists First :  1.09 Second :  1.39
Pivot price 0.95
Supports First :  0.61 Second :  0.5
MAs MA(5) :  0.91 MA(20) :  0.89
MA(100) :  0.63 MA(250) :  0.71
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  27.9 D(3) :  30.6
RSI RSI(14): 50.2
52-week High :  1.73 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ABVC ] has closed above bottom band by 31.5%. Bollinger Bands are 111.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.95 - 0.96 0.96 - 0.96
Low: 0.84 - 0.84 0.84 - 0.85
Close: 0.85 - 0.86 0.86 - 0.86
Company Description

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

Headline News

Tue, 15 Apr 2025
ABVC BioPharma Reports Strong Financial Growth - TipRanks

Tue, 15 Apr 2025
ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements - MarketScreener

Tue, 15 Apr 2025
ABVC BioPharma Announces 2024 Financial Results - Yahoo Finance

Tue, 15 Apr 2025
ABVC BIOPHARMA, INC. SEC 10-K Report - TradingView

Mon, 31 Mar 2025
ABVC BioPharma Delays Yearly Report Filing - TipRanks

Fri, 07 Mar 2025
ABVC BioPharma announces CFO resignation, CEO steps in as interim - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 24 (M)
Held by Insiders 9.4e+006 (%)
Held by Institutions 21.9 (%)
Shares Short 258 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.26e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 17.1 %
Return on Assets (ttm) -25.3 %
Return on Equity (ttm) -102.4 %
Qtrly Rev. Growth 2 %
Gross Profit (p.s.) 1062.72
Sales Per Share 1.54482e+006
EBITDA (p.s.) 1.12067e+006
Qtrly Earnings Growth -0.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0.4
Stock Dividends
Dividend 0
Forward Dividend 321400
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android